High uptake of RSU 1069 and its analogues into melanotic melanomas
- 1 July 1989
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 24 (1) , 28-32
- https://doi.org/10.1007/bf00254101
Abstract
RSU 1069 and RSU 1164 are electron affinic agents that contain a nitro group together with a weakly basic alkylating aziridine moiety, and they represent lead compounds in the development of dual-function, bioreductive, hypoxic cell radiosensitizers. We studied the pharmacokinetics of these drugs in mice carrying KHT sarcoma, Lewis lung carcinoma, and B16 melanoma. Following an i.p. dose of 80 mg/kg, absorption was rapid and the elimination t1/2 was in the region of 30 min for both agents. Maximal tumour levels were 91, 16 and 19 μg/ml for RSU 1069 and 109, 26 and 28 μg/ml for RSU 1164 in the B16, KHT and Lewis lung tumours, respectively. In B16 melanoma these levels corresponded to tumour:plasma ratios of 3.8 for RSU 1069 and 3.7 for RSU 1164. Cellular uptake of RSU 1069, RSU 1164 and a related compound, RB 7040, was measured in vitro as a function of extracellular pH. Melanotic cells from both B16 melanoma and HX118, a human tumour xenograft, showed substantially greater accumulation of these weakly basic sensitizers than any other cell type examied. Ratios of intra-:extracellular concentration (ci/Ce) for RSU 1069 were around unity and independent of pH for Lewis lung cells and HX34 amelanotic melanoma cells, whereas ratios of up to 3 and 5 were obtained in B16 and HX118 cells, respectively. The highest measured value of Ci/Ce was 15 for RSU 1164 in HX118 cells at pH 8.4; this compares with a ratio of 1.5 for HX34 cells at the same pH. These studies indicate that the high levels of uptake of the weakly basic sensitizers into melanotic melanoma in vivo is a cellmediated phenomenon and may be due to a lower average intracellular pH in the melanotic cells.This publication has 22 references indexed in Scilit:
- Radiotherapy using the hypoxic cell sensitizer Ro 03-8799 in malignant melanomaRadiotherapy and Oncology, 1987
- MECHANISM OF ACTION OF SOME BIOREDUCIBLE 2-NITROIMIDAZOLES - COMPARISON OF INVITRO CYTOTOXICITY AND ABILITY TO INDUCE DNA STRAND BREAKAGE1987
- A comparison of the tumour concentrations obtainable with misonidazole and Ro 03–8799The British Journal of Radiology, 1986
- Studies on the mechanisms of the radiosensitizing and cytotoxic properties of RSU-1069 and its analoguesInternational Journal of Radiation Oncology*Biology*Physics, 1986
- Primary radiotherapy of larynx and pharynx carcinoma—An analysis of some factors influencing local control and survivalInternational Journal of Radiation Oncology*Biology*Physics, 1986
- The differential cytotoxicity of RSU 1069: Cell survival studies indicating interaction with DNA as a possible mode of actionBritish Journal of Cancer, 1986
- Radiation sensitization and chemopotentiation: Rsu 1069, a compound more efficient than misonidazole in vitro and in vivoBritish Journal of Cancer, 1984
- The radiosensitizer Ro 03-8799 and the concentrations which may be achieved in human tumours: a preliminary studyBritish Journal of Cancer, 1982
- Clonal variation in the sensitivity of B16 melanoma to m-AMSABritish Journal of Cancer, 1982
- Stem-cell survival and tumor control in the Lewis lung carcinoma.1975